Diamond, Eli L.
Durham, Benjamin H.
Ulaner, Gary A.
Drill, Esther
Buthorn, Justin
Ki, Michelle
Bitner, Lillian
Cho, Hana
Young, Robert J.
Francis, Jasmine H.
Rampal, Raajit
Lacouture, Mario
Brody, Lynn A.
Ozkaya, Neval
Dogan, Ahmet
Rosen, Neal
Iasonos, Alexia
Abdel-Wahab, Omar
Hyman, David M.
Article History
Received: 9 November 2018
Accepted: 11 February 2019
First Online: 13 March 2019
Competing interests
: The authors declare the following competing interests: E.L.D., grants from Erdheim–Chester Disease Global Alliance, The Histiocytosis Association, the Society of Memorial Sloan Kettering, the Translational and Integrative Medicine Award of Memorial Sloan Kettering, the American Society for Clinic Oncology, and the Frame Fund; B.H.D., grants from National Cancer Institute, American Society of Hematology and Erdheim–Chester Disease Global Alliance Foundation; G.U. personal fees from Sanofi and grants from Sanofi, Novartis and Genentech; R.J.Y., personal fees from Agios, PUMA, NordicNeuroLabs and Icon, and grants from Agios; R.R., personal fees from Incyte, Celgene, Agios, Jazz, BeyondSpring, Apexx and Partner Therapeutics, and research funding from Stemline and Constellation; M.L., personal fees and royalties from Roche/Genentech, and research funding from Veloce, Berg and US Biotest; A.D., personal fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene and Novartis, and grants from National Cancer Institute and Roche; N.R., personal fees from Array BioPharma, Millennium Pharmaceuticals, AstraZeneca/MedImmune, Novartis, Eli Lilly, Boehringer Ingelheim, Merrimack Pharmaeutics, Chugai, Beigene, Daiichi Sankyo, Kura Oncology, ZAI Lab, F-Prime and Kadmon, and grants from Chugai, Bayer and Tarveda; A.I., personal fees from Mylan; O.A.-W., grants from National Cancer Institute, National Heart Lung and Blood Institute and H3B Biomedicine, and personal fees from H3B Biomedicine, Foundation Medicine, Merck and Jansen; D.M.H., personal fees from Atara Biotherapeutics, Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiopharm Group and Genetech, and grants from National Cancer Institute, AstraZeneca, Puma Biotechnology, Loxo Oncology, Bayer Pharmaceuticals, and The Nonna's Garden Foundation Initiative in Precision Oncology. The remaining authors have nothing to disclose.